• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食管癌转换手术后出现的药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS):一例报告

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Following Conversion Surgery for Esophageal Cancer: A Case Report.

作者信息

Yasuda Hiromi, Ichikawa Takashi, Yoshiyama Shigeyuki, Ohi Masaki, Toiyama Yuji

机构信息

Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Tsu, JPN.

出版信息

Cureus. 2025 Aug 4;17(8):e89366. doi: 10.7759/cureus.89366. eCollection 2025 Aug.

DOI:10.7759/cureus.89366
PMID:40918784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12409758/
Abstract

Conversion surgery is increasingly used for initially unresectable esophageal cancer patients responding to induction therapy. The integration of immune checkpoint inhibitors (ICIs) into standard chemotherapy regimens is expected to increase the number of patients undergoing this approach. However, ICIs can cause immune-related adverse events (irAEs), which are often difficult to diagnose in the postoperative setting. Among these, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but potentially life-threatening complication. A 71-year-old woman with stage IVA esophageal squamous cell carcinoma received induction chemotherapy, including nivolumab, fluorouracil, and cisplatin, followed by successful conversion surgery. Postoperatively, she developed fever, widespread rash, eosinophilia, and liver dysfunction. Initial suspicion was sepsis, and broad-spectrum antibiotics were started. However, repeated tests showed no infection. The retrospective review met the criteria for DRESS syndrome, with the postoperative contrast agent likely triggering the reaction. Supportive care and discontinuation of unnecessary antibiotics led to gradual improvement, and she was discharged for rehabilitation. This case highlights the diagnostic challenge of hypersensitivity reactions such as DRESS in the postoperative setting after ICI-based therapy. Although not a classical irAE, ICI-induced immune dysregulation may have contributed to its development. Awareness of atypical irAEs is essential for timely diagnosis and appropriate management.

摘要

转化手术越来越多地用于对诱导治疗有反应的初始不可切除食管癌患者。将免疫检查点抑制剂(ICI)纳入标准化疗方案有望增加接受这种治疗方法的患者数量。然而,ICI可引起免疫相关不良事件(irAE),在术后环境中往往难以诊断。其中,药物性嗜酸性粒细胞增多和全身症状(DRESS)综合征是一种罕见但可能危及生命的并发症。一名71岁的IV A期食管鳞状细胞癌女性接受了诱导化疗,包括纳武单抗、氟尿嘧啶和顺铂,随后成功进行了转化手术。术后,她出现发热、广泛皮疹、嗜酸性粒细胞增多和肝功能障碍。最初怀疑是败血症,于是开始使用广谱抗生素。然而,反复检查未发现感染。回顾性评估符合DRESS综合征的标准,术后造影剂可能引发了该反应。支持性治疗和停用不必要的抗生素导致病情逐渐好转,她出院进行康复治疗。该病例凸显了基于ICI治疗后术后环境中如DRESS等超敏反应的诊断挑战。尽管不是典型的irAE,但ICI诱导的免疫失调可能促成了其发生。认识非典型irAE对于及时诊断和适当管理至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/ae72ba2dd24c/cureus-0017-00000089366-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/f15997ccb4c1/cureus-0017-00000089366-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/4b07f20a975f/cureus-0017-00000089366-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/21b58469e53f/cureus-0017-00000089366-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/ae72ba2dd24c/cureus-0017-00000089366-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/f15997ccb4c1/cureus-0017-00000089366-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/4b07f20a975f/cureus-0017-00000089366-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/21b58469e53f/cureus-0017-00000089366-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7355/12409758/ae72ba2dd24c/cureus-0017-00000089366-i04.jpg

相似文献

1
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Following Conversion Surgery for Esophageal Cancer: A Case Report.食管癌转换手术后出现的药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS):一例报告
Cureus. 2025 Aug 4;17(8):e89366. doi: 10.7759/cureus.89366. eCollection 2025 Aug.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Clinical diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: An EAACI position paper.儿童药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS)的临床诊断与管理:欧洲变态反应和临床免疫学会立场文件
Pediatr Allergy Immunol. 2025 Jul;36(7):e70103. doi: 10.1111/pai.70103.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Ophthalmia Neonatorum新生儿眼炎
7
Systemic Inflammatory Response Syndrome全身炎症反应综合征
8
Comparing immunopathogenesis of non-human immunodeficiency virus immune reconstitution inflammatory syndrome and immune-related adverse events: A prospective multicenter cohort study.非人类免疫缺陷病毒免疫重建炎症综合征与免疫相关不良事件的免疫发病机制比较:一项前瞻性多中心队列研究。
J Dermatol. 2025 Jun;52(6):1015-1030. doi: 10.1111/1346-8138.17706. Epub 2025 Mar 29.
9
Drug Reaction With Eosinophilia and Systemic Symptoms: A Systematic Review.药物相关性嗜酸性粒细胞增多和全身症状:系统评价。
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1856-1868. doi: 10.1016/j.jaip.2023.02.035. Epub 2023 Mar 7.
10
Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review.细小病毒B19感染和阿替利珠单抗所致纯红细胞再生障碍性贫血:病例报告及文献综述
Immunotherapy. 2025 Aug 21:1-7. doi: 10.1080/1750743X.2025.2549675.

本文引用的文献

1
Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025.2025年药物超敏反应伴嗜酸性粒细胞增多和系统症状(DIHS/DRESS)诊断与治疗的最新进展
Allergol Int. 2025 Jul;74(3):372-379. doi: 10.1016/j.alit.2025.03.007. Epub 2025 Apr 17.
2
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.免疫检查点抑制剂诱发的伴有嗜酸性粒细胞增多和全身症状的药物反应:13例国际队列研究
Melanoma Res. 2023 Apr 1;33(2):155-158. doi: 10.1097/CMR.0000000000000877. Epub 2023 Feb 6.
3
Azathioprine-induced hypersensitivity reaction mimicking sepsis in a patient with systemic lupus erythematosus.
一名系统性红斑狼疮患者出现类似脓毒症的硫唑嘌呤诱导的超敏反应。
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):74-77. doi: 10.1093/mrcr/rxac061.
4
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
5
Nivolumab-associated DRESS in a genetic susceptible individual.纳武利尤单抗相关药物超敏反应综合征在遗传易感性个体中的发生。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-002879.
6
Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome.病例报告:一例甲氧苄啶/磺胺甲恶唑引发的低血压休克:与免疫检查点抑制剂及药物性超敏反应综合征相关的细胞因子释放综合征
Front Oncol. 2021 Apr 30;11:681997. doi: 10.3389/fonc.2021.681997. eCollection 2021.
7
The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity.免疫调节网络在严重药物超敏反应中的作用
Front Immunol. 2021 Feb 26;12:597761. doi: 10.3389/fimmu.2021.597761. eCollection 2021.
8
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者(ATTRACTION-3):一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
9
Nivolumab-associated DRESS syndrome: A case report.纳武单抗相关的药物超敏反应伴嗜酸性粒细胞增多和系统症状综合征:一例报告。
JAAD Case Rep. 2019 Feb 12;5(3):216-218. doi: 10.1016/j.jdcr.2018.11.017. eCollection 2019 Mar.
10
C-Reactive Protein and Procalcitonin in Case Reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.C-反应蛋白和降钙素原在药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)综合征病例报告中的应用。
Int Arch Allergy Immunol. 2018;176(1):44-54. doi: 10.1159/000487670. Epub 2018 Apr 13.